Staccato® Granisetron Multiple Dose PK

Study Overview
=================
Brief Summary
-----------------
To examine the tolerability and safety of AZ-010 following 7 days of dosing (up to 3 mg) in healthy volunteers To characterize the pharmacokinetics of AZ-010 following 7 days of dosing (up to 3 mg) in healthy volunteers

Detailed Description
-----------------
A Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetic Profile of Staccato Granisetron (AZ-010) in Healthy Volunteers

Official Title
-----------------
A Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetic Profile of Staccato Granisetron (AZ-010) in Healthy Volunteers

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Combination Product: 0.5mg AZ-010
* Combination Product: 1mg AZ-010
* Combination Product: 3mg AZ-010


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy based on a medical evaluation including history, physical examination, vital signs, electrocardiograms (ECGs) and laboratory tests assessed at the screening visit and prior to the first dose of study drug. Body weight ≥ 50 kg and BMI within the range of 18 to 32 kg/m2, inclusive, at screening. Negative urine tests for selected drugs of abuse and alcohol breath test at screening and Day 1. Exclusion Criteria: Any significant medical condition

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cohort 1<br>Single orally-inhaled dose | Combination Product: 0.5mg AZ-010<br>* Subject will receive a single inhaled dose (0.5mg) of AZ-010 or matching Staccato Placebo<br>* Other names: Staccato Placebo;|
| Experimental: Cohort 2<br>Single orally-inhaled dose | Combination Product: 1mg AZ-010<br>* Subject will receive a single inhaled dose (1mg) of AZ-010 or matching Staccato Placebo<br>* Other names: Staccato Placebo;|
| Experimental: Cohort 3<br>Single orally-inhaled dose | Combination Product: 3mg AZ-010<br>* Subject will receive a single inhaled dose (3mg) of AZ-010 or matching Staccato Placebo<br>* Other names: Staccato Placebo;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]). | Number of Subjects with Adverse Events as a measure of Safety and Tolerability | 8 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of Granisetron Exposure in Plasma | AUC | 8 days | 
| Measurement of Granisetron Maximum exposure in Plasma | Cmax | 8 days | 
| Measurement of Granisetron Time to Maximum Exposure in Plasma | Tmax | 8 days |